Recently it has been shown in numerous reports that aberrant activation of EMT and an associated cancer stem cell phenotype are considered a major cause of drug therapy resistance in aggressive solid tumors such as pancreatic cancer, lung cancer, and melanoma, particularly emphasizing the important role of the EMT-activator, ZEB1 in conferring stemness and resistance [43–46]. The gene discussed is ZEB1; the disease is lung cancer.